Synthetic advanced biologics

Produced with programmable bacteria

Engineering synthetic advanced biologics.

We are building a synthetic biology platform to develop synthetic advanced biologics capable of multi-tasking therapeutic activities, packing all the advantages of combination therapy in a single agent to provide safer and more efficient treatments.

Pipeline png v2.png

Synthetic advanced biologics
the next 
 generation drugs.


Founding team


For this seeker of disruptive technologies, who is passionate about biotechnology and entrepreneurship, drugs derived from engineered organisms are the next therapeutic revolution.


Kevin Neil, PhD
Co-Founder & CTO

Kevin, an exceptional synthetic biologist, turned the radically new technological approach developed by TATUM  into a reality. He is convinced that applying synthetic biology principles to the engineering of drugs holds great promise.


Sébastien Rodrigue, PhD
Co-Founder & CSO

Professor at the Université de Sherbrooke, Sébastien has positioned his laboratory at the forefront of Canadian synthetic biology. His profound desire to have a positive impact on the world led him to imagine the breakthrough technologies.


Louise Proulx.jpg

With 30 years in the pharma industry, Louise has held VP positions in successful companies and was former head of Vertex Pharmaceutical Canada. She also worked in the VC sector at Therillia and Sanderling.


Equity research analyst in the pharma sectors, Pierre has worked for several financial institutions (BGC Partners, Bryan, Garnier & Co, ODDO BHF) and participated in the IPO of Moderna. He currently is Director Equity Analyst Healthcare at UBP, Geneva.

L Gagnon.jpg

Lyne spent 20 years at ProMetic where she was VP R&D and pre-clinical studies. She successfully brought seven drugs to clinical trials and two of them are now approved. She currently is a  consultant in preclinical studies for fibrosis and cancer therapies.

Medical Advisors

Photo kaufman.jpg

Dr. Kaufman is a leading authority on local tumor immunotherapy. He played a key role in the clinical studies of the anti-PD-L1 Avelumab and the T-VEC oncolytic virus. Dr Kaufman is currently the CEO of Ankyra Therapeutics.


Dr. Champiat is head of the Inpatient Unit in the Drug Development Department at the Gustave Roussy Cancer Campus. He is a rising star in the intratumoral therapy field and strong beleiver this administration route will revolutionize the treatment of cancers.


Dr. Gerald Batist is director of the Department of Oncology at the Montréal Jewish General Hospital and director of McGill University’s Centre for Translational Research in Cancer. He works on novel therapeutics and made significant contributions to the development of new cancer treatments. 


Let's get in touch.

Are you interested in collaborating with us? Feel free to contact us. We are looking forward to hearing from you!

Thank you for contacting us!

Join us to create disruptive drugs!

At TATUM we are constantly looking for talented individuals who share our vision and are eager to develop synthetic advanced biologics.

If you want to join TATUM, please send your CV and motivation letter at:

Jobs_Email .jpg